Evidence map›Paper›PMID 27812214›Full record

ArticlePLoS pathogens2016

IFNAR1-Signalling Obstructs ICOS-mediated Humoral Immunity during Non-lethal Blood-Stage Plasmodium Infection.

Ismail Sebina, Kylie R James, Megan S F Soon, Lily G Fogg, Shannon E Best, Fabian de Labastida Rivera, Marcela Montes de Oca, Fiona H Amante, Bryce S Thomas, Lynette Beattie and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Overview of the host immune response toJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025
    Review
  7. Article
  8. Review
  9. CD4Nature communications · 2024
    Article
  10. NAD activates olfactory receptor 1386 to regulate type I interferon responses inProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Ismail SebinaMalaria Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Kylie R JamesMalaria Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Megan S F SoonMalaria Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Lily G FoggMalaria Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.ORCID http://orcid.org/0000-0002-7489-820X
Shannon E BestMalaria Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Fabian de Labastida RiveraImmunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.ORCID http://orcid.org/0000-0001-5241-2339
Marcela Montes de OcaImmunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Fiona H AmanteImmunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Bryce S ThomasMalaria Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Lynette BeattieImmunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Fernando Souza-Fonseca-GuimaraesImmunity in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute Herston, Queensland, Australia.
Mark J SmythImmunity in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute Herston, Queensland, Australia.
Paul J HertzogHudson Institute of Medical Research, Clayton, Victoria, Australia.
Geoffrey R HillBone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Andreas HutloffChronic Immune Reactions, German Rheumatism Research Centre (DRFZ), a Leibniz Institute, Berlin, Germany.ORCID http://orcid.org/0000-0002-0572-8151
Christian R EngwerdaImmunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Ashraful HaqueMalaria Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.ORCID http://orcid.org/0000-0003-2260-0026
QIMR Berghofer Medical Research Institute · AUThe University of Queensland · AUGerman Rheumatism Research Centre · DEHudson Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parasite-specific antibodies protect against blood-stage Plasmodium infection. However, in malaria-endemic regions, it takes many months for naturally-exposed individuals to develop robust humoral immunity. Explanations for this have focused on antigenic variation by Plasmodium, but have considered less whether host production of parasite-specific antibody is sub-optimal. In particular, it is unclear whether host immune factors might limit antibody responses. Here, we explored the effect of Type I Interferon signalling via IFNAR1 on CD4+ T-cell and B-cell responses in two non-lethal murine models of malaria, P. chabaudi chabaudi AS (PcAS) and P. yoelii 17XNL (Py17XNL) infection. Firstly, we demonstrated that CD4+ T-cells and ICOS-signalling were crucial for generating germinal centre (GC) B-cells, plasmablasts and parasite-specific antibodies, and likewise that T follicular helper (Tfh) cell responses relied on B cells. Next, we found that IFNAR1-signalling impeded the resolution of non-lethal blood-stage infection, which was associated with impaired production of parasite-specific IgM and several IgG sub-classes. Consistent with this, GC B-cell formation, Ig-class switching, plasmablast and Tfh differentiation were all impaired by IFNAR1-signalling. IFNAR1-signalling proceeded via conventional dendritic cells, and acted early by limiting activation, proliferation and ICOS expression by CD4+ T-cells, by restricting the localization of activated CD4+ T-cells adjacent to and within B-cell areas of the spleen, and by simultaneously suppressing Th1 and Tfh responses. Finally, IFNAR1-deficiency accelerated humoral immune responses and parasite control by boosting ICOS-signalling. Thus, we provide evidence of a host innate cytokine response that impedes the onset of humoral immunity during experimental malaria.

Indexed as

AnimalsAntibodies, ProtozoanB-LymphocytesCD4-Positive T-LymphocytesDisease Models, AnimalEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryImmunity, HumoralInducible T-Cell Co-Stimulator ProteinLymphocyte ActivationMalariaMiceMice, Inbred C57BLMice, KnockoutMicroscopy, ConfocalAntibodies, ProtozoanInducible T-Cell Co-Stimulator ProteinReceptor, Interferon alpha-beta

Identifiers

PMID27812214
PMCPMC5094753
OpenAlexW2548846041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.